Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
D Fanale, LR Corsini, R Scalia, C Brando… - Critical Reviews in …, 2022 - Elsevier
Alterations in short-repetitive DNA sequences, known as microsatellite instability (MSI), can
reflect deficiencies in Mismatch Repair (MMR) system which represents a major player in …
reflect deficiencies in Mismatch Repair (MMR) system which represents a major player in …
Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and meta-analysis
Importance The mismatch repair (MMR) pathway plays a crucial role in repairing DNA
replication errors in normal and cancer cells. Defects in DNA MMR proteins that determine …
replication errors in normal and cancer cells. Defects in DNA MMR proteins that determine …
[HTML][HTML] ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour …
Background Cancers with a defective DNA mismatch repair (dMMR) system contain
thousands of mutations most frequently located in monomorphic microsatellites and are …
thousands of mutations most frequently located in monomorphic microsatellites and are …
Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances
S Vranic - Biomolecules and Biomedicine, 2017 - bjbms.org
It is well-known that somatic mutations resulting in increased number of neoantigens
(“immunogenic antigens”) may enhance anti-tumor immune cell reaction. Also, high tumor …
(“immunogenic antigens”) may enhance anti-tumor immune cell reaction. Also, high tumor …
[HTML][HTML] How I treat MSI cancers with advanced disease
M Kok, M Chalabi, J Haanen - ESMO open, 2019 - Elsevier
Mismatch repair deficiency (dMMR) results in microsatellite instability (MSI) and is strongly
associated with responsiveness to programmed death-1 receptor (PD-1)-blocking …
associated with responsiveness to programmed death-1 receptor (PD-1)-blocking …
Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers
L Diaz, A Marabelle, TW Kim, R Geva… - Annals of …, 2017 - annalsofoncology.org
Background: A high level of microsatellite instability (MSI-H) is indicative of a tumor deficient
in mismatch repair (dMMR). Prior reports suggest that anti-PD-1 antibody therapy provides …
in mismatch repair (dMMR). Prior reports suggest that anti-PD-1 antibody therapy provides …
Comparison of standard mismatch repair deficiency and microsatellite instability tests in a large cancer series
ML Nádorvári, I Kenessey, A Kiss, T Barbai… - Journal of Translational …, 2024 - Springer
Background The tumor-agnostic indication of immune checkpoint inhibitors to treat cancers
with mismatch repair deficiency (dMMR)/microsatellite instability (MSI) increased the …
with mismatch repair deficiency (dMMR)/microsatellite instability (MSI) increased the …
[HTML][HTML] Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
Introduction Microsatellite instability (MSI) testing and tumor mutational burden (TMB) are
genomic biomarkers used to identify patients who are likely to benefit from immune …
genomic biomarkers used to identify patients who are likely to benefit from immune …
Immunotherapy of MSI Cancer: Facts and Hopes
HC Wilbur, DT Le, P Agarwal - Clinical Cancer Research, 2024 - AACR
Microsatellite instability (MSI) is a tumor molecular phenotype that evolves from loss of
function in the mismatch repair (MMR) proteins through deleterious germline mutations …
function in the mismatch repair (MMR) proteins through deleterious germline mutations …
Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
L Nebot-Bral, C Coutzac, PL Kannouche, N Chaput - Bulletin Du Cancer, 2019 - Elsevier
In the last few years, immunotherapy has revolutionized the oncology landscape by
targeting the host immune system. Blocking immune checkpoints such as cytotoxic T …
targeting the host immune system. Blocking immune checkpoints such as cytotoxic T …